Do You Need Menopause Hormone Therapy?

Who Actually Benefits From Menopause Hormone Therapy

Women with moderate-to-severe hot flashes, night sweats, or genitourinary syndrome of menopause (GSM) gain the clearest benefit from MHT. The 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS) identifies symptomatic women under age 60 or within 10 years of menopause onset as the population with the most favorable benefit-risk ratio 1.

About 80% of women experience vasomotor symptoms (VMS) during the menopausal transition, and roughly 25% report symptoms severe enough to interfere with daily function 2. For this subset, MHT provides relief that no other intervention matches. A Cochrane review of 24 trials (N=3,329) found oral estrogen reduced hot flash frequency by 75% and severity by 87% compared to placebo 3.

Women who experience premature ovarian insufficiency (before age 40) or early menopause (before age 45) represent a separate category. For them, hormone therapy is recommended at least until the average age of natural menopause (51) to prevent accelerated bone loss, cardiovascular risk, and cognitive decline associated with prolonged hypoestrogenism 4.

The Timing Hypothesis: Why "When" Matters More Than "Whether"

Starting MHT within 10 years of menopause onset or before age 60 is associated with cardiovascular benefit or neutral effect. Starting after age 60 or more than 10 years post-menopause carries higher cardiovascular risk. This is the "timing hypothesis," and two decades of data support it.

The Women's Health Initiative (WHI) enrolled women aged 50 to 79, with a mean age of 63. Many participants were over a decade past menopause. The initial 2002 results showed increased coronary events in the combined estrogen-progestogen arm 5. But age-stratified reanalysis told a different story. Women aged 50 to 59 who received conjugated equine estrogen alone had a hazard ratio of 0.63 for coronary heart disease mortality during 18-year cumulative follow-up 6.

The Danish Osteoporosis Prevention Study (DOPS) randomized 1,006 recently menopausal women (mean age 50) to hormone therapy or no treatment for 10 years. After 16 years of follow-up, the treatment group showed significantly reduced mortality (HR 0.57 to 95% CI 0.30-0.87) and heart failure hospitalizations without increased cancer, stroke, or venous thromboembolism 7.

The Endocrine Society's 2019 guideline states: "For women with bothersome menopausal symptoms who are within 10 years of menopause onset and have no contraindications, we recommend initiating MHT" 8.

What Symptoms MHT Treats Most Effectively

MHT addresses multiple estrogen-deficiency symptoms simultaneously. Hot flashes and night sweats respond fastest, often within two to four weeks of starting treatment.

Genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary urgency, recurrent UTIs) affects up to 84% of postmenopausal women and, unlike VMS, does not resolve over time without treatment 9. Low-dose vaginal estrogen is the first-line therapy for isolated GSM and carries minimal systemic absorption. Serum estradiol levels with vaginal estrogen remain within the normal postmenopausal range 10.

Sleep disruption linked to night sweats improves with MHT. The KEEPS (Kronos Early Estrogen Prevention Study) trial found that both oral conjugated equine estrogen and transdermal estradiol improved sleep quality scores significantly versus placebo over 48 months 11.

Joint pain is an underrecognized menopausal symptom. The WHI data showed a 15% reduction in joint pain among women receiving estrogen therapy compared to placebo 12.

Understanding the Risks: What the Data Actually Shows

Breast cancer risk remains the primary concern for most women considering MHT. The risk profile depends on the type and duration of therapy.

Estrogen-only therapy (for women without a uterus) showed no increased breast cancer risk in the WHI after 7.2 years of use. The extended follow-up at 20 years confirmed a non-significant reduction in breast cancer incidence (HR 0.78 to 95% CI 0.65-0.93) 13. Combined estrogen-progestogen therapy showed a small increase in breast cancer after approximately 5 years of continuous use, with an attributable risk of fewer than 1 additional case per 1,000 women per year 5.

Micronized progesterone may carry lower breast cancer risk than synthetic progestins. The E3N French cohort study (N=80,377) found no increased breast cancer risk with estrogen plus micronized progesterone over a mean follow-up of 8.1 years, while synthetic progestins were associated with elevated risk 14.

Venous thromboembolism (VTE) risk increases 2-fold with oral estrogen. Transdermal estradiol at standard doses does not appear to increase VTE risk, making it preferable for women with elevated baseline thrombotic risk or BMI over 30 15.

Stroke risk increases modestly with oral estrogen (approximately 1 additional stroke per 1,000 women per year in WHI). Transdermal estradiol at doses of 50 mcg or less has not been associated with increased stroke risk in observational studies 16.

Choosing the Right Formulation

The route of administration changes the risk profile significantly. Transdermal estradiol bypasses first-pass hepatic metabolism, avoiding increases in clotting factors, triglycerides, and inflammatory markers seen with oral estrogen.

Standard systemic options include:

Transdermal estradiol patches (0.025 to 0.1 mg/day) or gel preparations deliver steady-state levels without hepatic effects. The NICE guideline on menopause (2015, updated 2019) recommends transdermal as first-line for women with migraine, hypertriglyceridemia, or elevated VTE risk 17.

Oral estradiol (0.5 to 2 mg/day) or conjugated equine estrogen (0.3 to 0.625 mg/day) remain options for women without VTE risk factors who prefer tablets.

For women with an intact uterus, a progestogen must accompany systemic estrogen to prevent endometrial hyperplasia. Options include micronized progesterone 100 to 200 mg orally for 12 to 14 days/month (cyclic) or 100 mg nightly (continuous), the levonorgestrel IUS (52 mg), or medroxyprogesterone acetate 2.5 to 5 mg daily 18.

Vaginal estrogen (cream, tablet, or ring) treats GSM locally. The 10 mcg estradiol vaginal tablet or the 2 mg estradiol vaginal ring (Estring) do not require concomitant progestogen 10.

Tissue-selective estrogen complex (TSEC), combining conjugated estrogens with bazedoxifene, provides endometrial protection without a progestogen. It is FDA-approved for VMS and osteoporosis prevention 19.

When MHT Is Not Appropriate

Absolute contraindications to systemic MHT include active or history of breast cancer, coronary heart disease, prior stroke or transient ischemic attack, active venous thromboembolism, active liver disease, and unexplained vaginal bleeding 1.

Relative contraindications require careful evaluation. These include a strong family history of breast cancer (particularly BRCA carriers), history of endometrial cancer, and uncontrolled hypertension. For BRCA carriers without personal cancer history, the decision is individualized; some data suggest no additional breast cancer risk from short-term MHT use after risk-reducing salpingo-oophorectomy 20.

Women over 60 initiating systemic MHT for the first time face an unfavorable benefit-risk ratio for cardiovascular outcomes. The 2017 Hormone Therapy Position Statement from NAMS advises against initiating systemic therapy solely for chronic disease prevention in this population 1.

Non-Hormonal Alternatives That Work

For women who cannot or prefer not to use MHT, several evidence-based alternatives exist. They are less effective than estrogen for VMS but still provide meaningful relief.

Fezolinetant (Veozah), approved by the FDA in May 2023, is a neurokinin 3 receptor antagonist that reduced moderate-to-severe hot flashes by 60% versus placebo in the SKYLIGHT 1 trial (N=501) at 12 weeks 21. It is the first non-hormonal prescription specifically designed for VMS.

Paroxetine mesylate 7.5 mg (Brisdelle) is FDA-approved for VMS and reduces hot flash frequency by approximately 33 to 50% 22. Other SSRIs and SNRIs (venlafaxine 75 mg, escitalopram 10 to 20 mg) also show efficacy in randomized trials, though they are off-label for this indication.

Cognitive behavioral therapy (CBT) reduces hot flash bother and improves sleep without medication. The MENOS 2 trial demonstrated CBT maintained benefits at 26-week follow-up 23.

Gabapentin 900 mg/day reduces hot flash frequency by about 45% but causes sedation and dizziness 24.

Oxybutynin 2.5 to 5 mg twice daily reduced VMS by 80% in a small randomized trial (N=150), though anticholinergic side effects limit its use in older adults 25.

How Long Should You Stay on MHT

There is no universal time limit. The previous "use the lowest dose for the shortest time" mantra from the early 2000s has been replaced by individualized duration assessment.

The 2022 NAMS position statement recommends periodic reassessment (every 1 to 2 years) rather than mandatory discontinuation at 5 years 1. For women who remain symptomatic, continuing MHT may be appropriate beyond age 60 if the benefits outweigh the risks after shared decision-making.

Women who stop MHT can expect VMS recurrence in approximately 50% of cases, regardless of whether discontinuation is abrupt or tapered 26. The median duration of VMS is 7.4 years from onset, per the Study of Women's Health Across the Nation (SWAN), and some women experience symptoms for over a decade 27.

For GSM specifically, vaginal estrogen can be continued indefinitely. The American College of Obstetricians and Gynecologists (ACOG) states that low-dose vaginal estrogen can be used for as long as symptoms persist without arbitrary time limits 28.

The Decision Framework: Questions to Ask Your Clinician

The decision to start MHT is not binary. It requires assessing symptom burden against individual risk.

Questions that shape the decision:

How severe are your symptoms on a daily basis? Mild symptoms that don't impair function or sleep may respond to lifestyle measures alone. Moderate-to-severe symptoms that disrupt work, relationships, or sleep are the clearest indication for MHT.

How old are you and when did menopause begin? Women under 60, or within 10 years of their final period, are in the optimal window for initiating systemic MHT with a favorable benefit-risk ratio 8.

Do you have an intact uterus? This determines whether you need combined therapy (estrogen plus progestogen) or can use estrogen alone.

What is your cardiovascular risk profile? Women with hypertension, diabetes, obesity, or smoking history need individualized assessment. Transdermal estradiol is preferred when VTE or stroke risk is elevated 15.

What is your breast cancer risk? Women at average risk can use combined MHT for at least 5 years with minimal absolute risk increase. Women at elevated risk (Gail score >1.67%, dense breasts, first-degree relative with breast cancer) should discuss whether estrogen-only, TSEC, or non-hormonal options are more appropriate.

Do you have bone density concerns? MHT prevents osteoporotic fractures. The WHI showed a 33% reduction in hip fractures with combined therapy 5. For women with osteopenia who also have menopausal symptoms, MHT serves dual purposes.

Monitoring While on MHT

Women on systemic MHT should have regular follow-up at 3 months after initiation, then annually. Monitoring includes blood pressure assessment, breast examination, and discussion of any new symptoms.

Mammography continues per standard screening guidelines (every 1 to 2 years depending on age and risk). Combined MHT increases mammographic density, which can reduce mammography sensitivity. Digital breast tomosynthesis may improve detection in women on MHT with dense breasts 29.

Endometrial monitoring is not routinely required for women on adequate progestogen. Unscheduled bleeding after the first 6 months of continuous combined therapy warrants transvaginal ultrasound or endometrial biopsy 18.

Bone density testing (DXA) is appropriate for women using MHT for osteoporosis prevention, repeated every 2 years to confirm response.

Annual reassessment of the benefit-risk ratio should include updated cardiovascular risk calculation, review of family history changes, and patient preference for continuation versus discontinuation.